Compare CVGI & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVGI | CNTB |
|---|---|---|
| Founded | 2000 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.7M | 135.7M |
| IPO Year | 2004 | 2020 |
| Metric | CVGI | CNTB |
|---|---|---|
| Price | $4.51 | $2.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | ★ 657.7K | 451.1K |
| Earning Date | 05-05-2026 | 08-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 316.18 | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $755,231,000.00 | $64,000.00 |
| Revenue This Year | $4.84 | N/A |
| Revenue Next Year | $5.36 | N/A |
| P/E Ratio | $110.00 | ★ N/A |
| Revenue Growth | ★ 14.06 | N/A |
| 52 Week Low | $1.29 | $1.23 |
| 52 Week High | $5.88 | $3.82 |
| Indicator | CVGI | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 41.13 | 61.59 |
| Support Level | $3.73 | $2.30 |
| Resistance Level | $4.45 | $2.68 |
| Average True Range (ATR) | 0.40 | 0.18 |
| MACD | -0.07 | 0.06 |
| Stochastic Oscillator | 8.15 | 91.53 |
Commercial Vehicle Group Inc and its subsidiaries are a globalised provider of systems, assemblies, and components to international commercial vehicle markets and electric vehicle markets. It delivers real solutions to complex design, engineering, and manufacturing problems while creating positive change for customers, industries, and communities it serves. The company has its manufacturing operations in the United States, Mexico, China, the United Kingdom, the Czech Republic, Ukraine, Morocco, Thailand, India, and Australia. Organisations' products are mainly sold in North America, Europe, and the Asia-Pacific region. It has three segments: Global Seating Segment, Global Electrical systmem, and Trim Systems and Components Segment, with the majority of revenue from Global Seating Segment.
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.